Intervention not reported
Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with severe or life‐threatening bleeding compared with placebo or standard care (very low certainty).
1 finding from 1 review
Number of days on which bleeding occurred ‐ not measured · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to first bleeding episode (days) · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
Number of platelet transfusions per participant up to 30 days from study entry · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Thromboembolic events · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether the intervention changes number of participants with at least 1 bleeding episode (very low certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review